Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mobistarr is a topical analgesic and anti-inflammatory gel formulation containing a combination of diclofenac diethylamine (1.16%), linseed oil (3%), methyl salicylate (10%), and menthol (5%). Developed by Sunlife Pharmaceuticals, it is designed for the localized relief of pain and inflammation associated with musculoskeletal disorders, joint pain, osteoarthritis, sprains, strains, and bruises. Diclofenac diethylamine acts as a non-steroidal anti-inflammatory drug (NSAID) by inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis. Methyl salicylate and menthol function as counterirritants, with menthol activating TRPM8 channels to produce a cooling sensation and dilate blood vessels, while methyl salicylate provides local anesthetic and anti-inflammatory effects. Linseed oil acts as an emollient and anti-inflammatory agent, helping to soothe the skin and enhance the penetration of the active ingredients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac diethylamine + linseed oil + menthol + methyl salicylate (Sun Pharma).